{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:02:30Z","timestamp":1772136150236,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klionsky Fellowship"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA121973"],"award-info":[{"award-number":["P50CA121973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA121973"],"award-info":[{"award-number":["P50CA121973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015938","name":"Hillman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015938","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015689","name":"GIST Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015689","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Life Raft Group","award":["AD-UPCC"],"award-info":[{"award-number":["AD-UPCC"]}]},{"name":"Pittsburgh Cure Sarcoma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although\n                    <jats:italic>KIT<\/jats:italic>\n                    -mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the\n                    <jats:italic>KIT<\/jats:italic>\n                    receptor tyrosine kinase gene indicating continued dependency on the KIT signaling pathway. The fact that the type of secondary mutation confers either sensitivity or resistance towards TKIs and the notion that secondary mutations exhibit intra- and intertumoral heterogeneity complicates the optimal choice of treatment in the imatinib-resistant setting. Therefore, new strategies that target KIT independently of its underlying mutations are urgently needed. Homoharringtonine (HHT) is a first-in-class inhibitor of protein biosynthesis and is FDA-approved for the treatment of chronic myeloid leukemia (CML) that is resistant to at least two TKIs. HHT has also shown activity in\n                    <jats:italic>KIT<\/jats:italic>\n                    -mutant mastocytosis models, which are intrinsically resistant to imatinib and most other TKIs. We hypothesized that HHT could be effective in GIST through downregulation of KIT expression and subsequent decrease of KIT activation and downstream signaling. Testing several GIST cell line models, HHT led to a significant reduction in nascent protein synthesis and was highly effective in the nanomolar range in IM-sensitive and IM-resistant GIST cell lines. HHT treatment resulted in a rapid and complete abolishment of KIT expression and activation, while KIT mRNA levels were minimally affected. The response to HHT involved induction of apoptosis as well as cell cycle arrest. The antitumor activity of HHT was confirmed in a GIST xenograft model. Taken together, inhibition of protein biosynthesis is a promising strategy to overcome TKI resistance in GIST.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-12000-2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T06:02:54Z","timestamp":1652853774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability"],"prefix":"10.1038","volume":"12","author":[{"given":"Donna M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha S.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parker T.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areej A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura D.","family":"Presutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kaczorowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nduka M.","family":"Amankulor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Shuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Duensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"12000_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577\u2013580 (1998).","journal-title":"Science"},{"key":"12000_CR2","first-page":"8118","volume":"61","author":"BP Rubin","year":"2001","unstructured":"Rubin, B. P. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118\u20138121 (2001).","journal-title":"Cancer Res."},{"key":"12000_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708\u2013710 (2003).","journal-title":"Science"},{"key":"12000_CR4","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1038\/sj.onc.1204704","volume":"20","author":"DA Tuveson","year":"2001","unstructured":"Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20, 5054\u20135058 (2001).","journal-title":"Oncogene"},{"key":"12000_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472\u2013480 (2002).","journal-title":"N. Engl. J. Med."},{"key":"12000_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij, J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364, 1127\u20131134 (2004).","journal-title":"Lancet"},{"key":"12000_CR7","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu, C. R. et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 11, 4182\u20134190 (2005).","journal-title":"Clin. Cancer Res."},{"key":"12000_CR8","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann, E. et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12, 1743\u20131749 (2006).","journal-title":"Clin. Cancer Res."},{"key":"12000_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368, 1329\u20131338 (2006).","journal-title":"Lancet"},{"key":"12000_CR10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","volume":"30","author":"S George","year":"2012","unstructured":"George, S. et al. Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J. Clin. Oncol. 30, 2401\u20132407 (2012).","journal-title":"J. Clin. Oncol."},{"key":"12000_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri, G. D. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 295\u2013302 (2013).","journal-title":"Lancet"},{"key":"12000_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay, J. Y. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 923\u2013934 (2020).","journal-title":"Lancet Oncol."},{"key":"12000_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Avapritinib: First approval. Drugs 80, 433\u2013439 (2020).","journal-title":"Drugs"},{"key":"12000_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","volume":"145","author":"RL Jones","year":"2021","unstructured":"Jones, R. L. et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur. J. Cancer 145, 132\u2013142 (2021).","journal-title":"Eur. J. Cancer"},{"key":"12000_CR15","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/sj.onc.1207525","volume":"23","author":"A Duensing","year":"2004","unstructured":"Duensing, A. et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999\u20134006 (2004).","journal-title":"Oncogene"},{"key":"12000_CR16","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.18632\/oncotarget.13882","volume":"8","author":"JL Rausch","year":"2017","unstructured":"Rausch, J. L. et al. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Oncotarget 8, 4471\u20134483 (2017).","journal-title":"Oncotarget"},{"key":"12000_CR17","doi-asserted-by":"publisher","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","volume":"66","author":"S Bauer","year":"2006","unstructured":"Bauer, S., Yu, L. K., Demetri, G. D. & Fletcher, J. A. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 66, 9153\u20139161 (2006).","journal-title":"Cancer Res."},{"key":"12000_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1158\/0008-5472.CAN-13-1955","volume":"74","author":"S Boichuk","year":"2014","unstructured":"Boichuk, S. et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 74, 1200\u20131213 (2014).","journal-title":"Cancer Res."},{"key":"12000_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/0008-5472.CAN-09-1449","volume":"70","author":"S Bauer","year":"2010","unstructured":"Bauer, S. et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 70, 150\u2013159 (2010).","journal-title":"Cancer Res."},{"key":"12000_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano, C. et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br. J. Cancer 120, 612\u2013620 (2019).","journal-title":"Br. J. Cancer"},{"key":"12000_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-62088-7","volume":"10","author":"JL Rausch","year":"2020","unstructured":"Rausch, J. L. et al. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Sci. Rep. 10, 1\u201314 (2020).","journal-title":"Sci. Rep."},{"key":"12000_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","volume":"20","author":"V Gandhi","year":"2014","unstructured":"Gandhi, V., Plunkett, W. & Cortes, J. E. Omacetaxine: A protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin. Cancer Res. 20, 1735\u20131740 (2014).","journal-title":"Clin. Cancer Res."},{"key":"12000_CR23","first-page":"511","volume":"11","author":"MT Huang","year":"1975","unstructured":"Huang, M. T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 11, 511\u2013519 (1975).","journal-title":"Mol. Pharmacol."},{"key":"12000_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","volume":"257","author":"RM Tujebajeva","year":"1989","unstructured":"Tujebajeva, R. M., Graifer, D. M., Karpova, G. G. & Ajtkhozhina, N. A. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett. 257, 254\u2013256 (1989).","journal-title":"FEBS Lett."},{"key":"12000_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","volume":"92","author":"HM Kantarjian","year":"2001","unstructured":"Kantarjian, H. M. et al. Homoharringtonine - History, current research, and future directions. Cancer 92, 1591\u20131605 (2001).","journal-title":"Cancer"},{"key":"12000_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40487-018-0058-6","volume":"6","author":"ES Winer","year":"2018","unstructured":"Winer, E. S. & DeAngelo, D. J. A Review of omacetaxine: A chronic myeloid leukemia treatment resurrected. Oncol. Ther. 6, 9\u201320 (2018).","journal-title":"Oncol. Ther."},{"key":"12000_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","volume":"72","author":"M Fresno","year":"1977","unstructured":"Fresno, M., Jimenez, A. & Vazquez, D. Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 72, 323\u2013330 (1977).","journal-title":"Eur. J. Biochem."},{"key":"12000_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","volume":"19","author":"F Alvandi","year":"2014","unstructured":"Alvandi, F. et al. U.S. food and drug administration approval summary: Omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist 19, 94\u201399 (2014).","journal-title":"Oncologist"},{"key":"12000_CR29","doi-asserted-by":"publisher","first-page":"16951","DOI":"10.18632\/oncotarget.4773","volume":"6","author":"NC Wolff","year":"2015","unstructured":"Wolff, N. C. et al. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget 6, 16951\u201316962 (2015).","journal-title":"Oncotarget"},{"key":"12000_CR30","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.CCR-19-2717","volume":"26","author":"TP Howard","year":"2020","unstructured":"Howard, T. P. et al. Rhabdoid tumors are sensitive to the protein-translation inhibitor homoharringtonine. Clin. Cancer Res. 26, 4995\u20135006 (2020).","journal-title":"Clin. Cancer Res."},{"key":"12000_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1535-7163.MCT-09-0468","volume":"9","author":"Y Jin","year":"2010","unstructured":"Jin, Y. et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol. Cancer Ther. 9, 211\u2013223 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/labinvest.3780461","volume":"82","author":"T Taguchi","year":"2002","unstructured":"Taguchi, T. et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab. Invest. 82, 663\u2013665 (2002).","journal-title":"Lab. Invest."},{"key":"12000_CR33","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1158\/0008-5472.CAN-08-4004","volume":"69","author":"T M\u00fchlenberg","year":"2009","unstructured":"M\u00fchlenberg, T. et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 69, 6941\u20136950 (2009).","journal-title":"Cancer Res."},{"key":"12000_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"12000_CR35","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1038\/sj.onc.1210558","volume":"26","author":"S Bauer","year":"2007","unstructured":"Bauer, S., Duensing, A., Demetri, G. D. & Fletcher, J. A. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase\/AKT is a crucial survival pathway. Oncogene 26, 7560\u20137568 (2007).","journal-title":"Oncogene"},{"key":"12000_CR36","first-page":"CD-20-0487","volume":"11","author":"S Grunewald","year":"2020","unstructured":"Grunewald, S. et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 11, CD-20-0487 (2020).","journal-title":"Cancer Discov."},{"key":"12000_CR37","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/0008-5472.CAN-06-3497","volume":"67","author":"Y Liu","year":"2007","unstructured":"Liu, Y. et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res. 67, 2685\u20132692 (2007).","journal-title":"Cancer Res."},{"key":"12000_CR38","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1158\/0008-5472.CAN-08-1935","volume":"68","author":"Y Liu","year":"2008","unstructured":"Liu, Y. et al. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res. 68, 9015\u20139023 (2008).","journal-title":"Cancer Res."},{"key":"12000_CR39","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1535-7163.MCT-18-1224","volume":"18","author":"T Muhlenberg","year":"2019","unstructured":"Muhlenberg, T. et al. KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1\/2 inhibition as salvage strategy. Mol. Cancer Ther. 18, 1985\u20131996 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR40","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1073\/pnas.1505787112","volume":"112","author":"M Shuda","year":"2015","unstructured":"Shuda, M. et al. CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation. Proc. Natl. Acad. Sci. 112, 5875\u20135882 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"12000_CR41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/neuonc\/now061","volume":"18","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro. Oncol. 18, 1402\u20131412 (2016).","journal-title":"Neuro. Oncol."},{"key":"12000_CR42","unstructured":"Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials. (2005)."},{"key":"12000_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","volume":"71","author":"J Nemunaitis","year":"2012","unstructured":"Nemunaitis, J. et al. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother. Pharmacol. 71, 35\u201341 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"12000_CR44","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1535-7163.MCT-11-0148","volume":"10","author":"G Floris","year":"2011","unstructured":"Floris, G. et al. The Heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of Gastrointestinal stromal tumors. Mol. Cancer Ther. 10, 1897\u20131908 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-19-1069","volume":"19","author":"A Garc\u00eda-Valverde","year":"2020","unstructured":"Garc\u00eda-Valverde, A. et al. Preclinical activity of PI3K inhibitor copanlisib in gastrointestinal stromal tumor. Mol. Cancer Ther. 19, 1289\u20131297 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR46","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-18-0815","volume":"25","author":"O-P Pulkka","year":"2019","unstructured":"Pulkka, O.-P. et al. Anagrelide for gastrointestinal stromal tumor. Clin. Cancer Res. 25, 1676\u20131687 (2019).","journal-title":"Clin. Cancer Res."},{"key":"12000_CR47","doi-asserted-by":"publisher","first-page":"8477","DOI":"10.1038\/srep08477","volume":"5","author":"W Cao","year":"2015","unstructured":"Cao, W. et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6\/JAK1\/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci. Rep. 5, 8477 (2015).","journal-title":"Sci. Rep."},{"key":"12000_CR48","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1038\/cddis.2012.149","volume":"3","author":"LM Lindqvist","year":"2012","unstructured":"Lindqvist, L. M. et al. Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis. 3, e409\u2013e419 (2012).","journal-title":"Cell Death Dis."},{"key":"12000_CR49","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1158\/1535-7163.MCT-09-0193","volume":"8","author":"L Rink","year":"2009","unstructured":"Rink, L. et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol. Cancer Ther. 8, 2172\u20132182 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR50","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-20-0973","volume":"20","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. KITlow cells mediate imatinib resistance in gastrointestinal stromal tumor. Mol. Cancer Ther. 20, 2035\u20132048 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"12000_CR51","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1080\/15384101.2018.1553335","volume":"17","author":"Y Tu","year":"2018","unstructured":"Tu, Y. et al. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. Cell Cycle 17, 2577\u20132592 (2018).","journal-title":"Cell Cycle"},{"key":"12000_CR52","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ijc.21164","volume":"117","author":"S Bauer","year":"2005","unstructured":"Bauer, S. et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int. J. Cancer 117, 316\u2013325 (2005).","journal-title":"Int. J. Cancer"},{"key":"12000_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","volume":"128","author":"M Debiec-Rychter","year":"2005","unstructured":"Debiec-Rychter, M. et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128, 270\u2013279 (2005).","journal-title":"Gastroenterology"},{"key":"12000_CR54","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1053\/j.gastro.2010.05.083","volume":"139","author":"MR Bardsley","year":"2010","unstructured":"Bardsley, M. R. et al. Kitlow stem cells cause resistance to Kit\/Platelet-Derived Growth Factor \u03b1 inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 139, 942\u2013952 (2010).","journal-title":"Gastroenterology"},{"key":"12000_CR55","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2400608","volume":"11","author":"G Visani","year":"1997","unstructured":"Visani, G. et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u2018in vitro\u2019 growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11, 624\u2013628 (1997).","journal-title":"Leukemia"},{"key":"12000_CR56","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1002\/cncr.24601","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama, A., Kantarjian, H. & Cortes, J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115, 5382\u20135393 (2009).","journal-title":"Cancer"},{"key":"12000_CR57","unstructured":"Safety Profile and Adverse Reactions | SYNRIBO (omacetaxine mepesuccinate) (accessed 5 August 2021); https:\/\/www.synribohcp.com\/Adverse_Reactions"},{"key":"12000_CR58","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/cncr.20968","volume":"103","author":"RG Maki","year":"2005","unstructured":"Maki, R. G. et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103, 1431\u20131438 (2005).","journal-title":"Cancer"},{"key":"12000_CR59","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ncponc0555","volume":"3","author":"T Caravita","year":"2006","unstructured":"Caravita, T., de Fabritiis, P., Palumbo, A., Amadori, S. & Boccadoro, M. Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. Nat. Clin. Pract. Oncol. 3, 374\u2013387 (2006).","journal-title":"Nat. Clin. Pract. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12000-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12000-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12000-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:52:43Z","timestamp":1669326763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12000-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12000"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12000-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.01.458633","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8275"}}